IP Library Granted Patent US 9,403,818
Granted Patent B2
US 9,403,818 · App. 13/823,187 · Granted Aug 2, 2016

Antimicrobial 4-oxoquinolizines

Inventors: Jutta Heim (Ramlinsburg, CH); Peter Schneider (Bottmingen/BL, CH); Patrick Roussel (Mulhouse, FR); Daniel Milligan (San Francisco, CA); Christian Bartels (Allschwil/BL, CH); Glenn Dale (Basel, CH)
Assignee: Emergent Product Development Gaithersburg Inc.
C07D455/02A61K31/4375A61K31/444A61K31/4545A61K31/4709A61K31/496A61K31/506A61K38/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,403,818
App. No.
13/823,187
Granted
Aug 2, 2016
Kind
B2
Abstract

This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

Claims (10)

1. A pharmaceutical composition comprising a Polymyxin and a 4-oxoquinolizine selected from

8-(4-amino-2,5-difluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;

8-(4-amino-3,5-dichloro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid;

8-(4-amino-3,5-difluoro-phenyl)-1-cyclopropyl-9-methyl-4-oxo-quinolizine-3-carboxylic acid; and

8-(4-amino-2,5-difluoro-phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid.

2. The pharmaceutical composition according to claim 1 , wherein the Polymyxin is selected from the group consisting of Polymyxin B and Polymyxin E.

3. The pharmaceutical composition according to claim 1 , wherein the polymyxin is present in a subinhibitory concentration.

4. A method of treatment of a bacterial infection in an individual in need thereof, said method comprising administering the composition according to claim 1 to said individual.

5. The method according to claim 4 , wherein said bacterial infection is infection by a multiresistant strain.

6. The method according to claim 4 , wherein the composition is for treatment of a bacterial infection in an individual in need thereof, and said infection is infection by one or more bacteria of a genus selected from the group consisting of Acinetobacter, Bacillus, Bordetella, Borrelia, Brucella, Camphylobacter, Chlamydia, Clostridium, Corynebacterium, Enterococcus, Escherichia, Fransisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Propionibacterium, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Vibrio and Yersinia.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 29, 2026
From: OHA AGENCY LLC, IN ITS CAPACITY AS ADMINISTRATIVE AGENT
To: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Reel/Frame 074509/0661 →
SECURITY INTEREST Recorded Sep 30, 2024
From: EMERGENT BIODEFENSE OPERATIONS LANSING LLC; EMERGENT BIOSOLUTIONS INC.; EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.; EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC; EMERGENT TRAVEL HEALTH INC.; EMERGENT BIOSOLUTIONS CANADA INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 068746/0698 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS Recorded Sep 3, 2024
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Reel/Frame 068829/0873 →
NOTICE OF GRANT OF SECURITY INTEREST IN U.S. PATENTS Recorded Sep 3, 2024
From: EMERGENT BIODEFENSE OPERATIONS LANSING LLC; EMERGENT BIOSOLUTIONS CANADA INC.; EMERGENT BIOSOLUTIONS INC.; EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC; EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.; EMERGENT TRAVEL HEALTH INC.
To: OHA AGENCY LLC
Reel/Frame 068828/0233 →
SECURITY INTEREST Recorded May 18, 2023
From: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 063690/0069 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2015
From: EVOLVA SA
To: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Reel/Frame 036213/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2013
From: HEIM, JUTTA; SCHNEIDER, PETER; ROUSSEL, PATRICK; MILLIGAN, DANIEL; BARTELS, CHRISTIAN; DALE, GLENN
To: EVOLVA SA
Reel/Frame 030532/0159 →
Continuity (2)
Provisional Application 61438543 · Feb 1, 2011
Related Publication 20130252882A1 · Sep 26, 2013